EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.
Over longer horizons, EBITDA CAGR averages 6.78% over 3 years and 4.61% over 5 years; the trailing 12 months came in at +16.89%. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.
Edwards Lifesciences Corporation (EW)
EBITDA growth vs the same quarter one year earlier, last 40 quarters.
Reported quarterly EBITDA; no daily interpolation.
| Year | Start EBITDA | End EBITDA | Change | % Change |
|---|---|---|---|---|
| 2025 | $1.53B | $1.79B | +$258.90M | +16.88% |
| 2024 | $1.57B | $1.53B | −$38.30M | -2.44% |
| 2023 | $1.87B | $1.57B | −$297.00M | -15.89% |
| 2022 | $1.77B | $1.87B | +$95.50M | +5.38% |
| 2021 | $1.43B | $1.77B | +$342.30M | +23.91% |
| 2020 | $1.31B | $1.43B | +$118.90M | +9.06% |
| 2019 | $1.17B | $1.31B | +$142.80M | +12.21% |
| 2018 | $1.09B | $1.17B | +$77.70M | +7.12% |
| 2017 | $886.70M | $1.09B | +$205.30M | +23.15% |
| 2016 | $641.70M | $886.70M | +$245.00M | +38.18% |
| 2015 | $555.80M | $641.70M | +$85.90M | +15.46% |
| 2014 | $501.70M | $555.80M | +$54.10M | +10.78% |
| 2013 | $454.00M | $501.70M | +$47.70M | +10.51% |
| 2012 | $387.10M | $454.00M | +$66.90M | +17.28% |
| 2011 | $339.00M | $387.10M | +$48.10M | +14.19% |
| 2010 | $291.70M | $339.00M | +$47.30M | +16.22% |
| 2009 | $264.60M | $291.70M | +$27.10M | +10.24% |
| 2008 | $224.30M | $264.60M | +$40.30M | +17.97% |
| 2007 | $220.30M | $224.30M | +$4.00M | +1.82% |
| 2006 | $231.80M | $220.30M | −$11.50M | -4.96% |
| 2005 | $210.10M | $231.80M | +$21.70M | +10.33% |
| 2004 | $184.00M | $210.10M | +$26.10M | +14.18% |
| 2003 | $92.50M | $184.00M | +$91.50M | +98.92% |
| 2002 | $81.00M | $92.50M | +$11.50M | +14.20% |
| 2001 | $169.00M | $81.00M | −$88.00M | -52.07% |
| 2000 | $201.00M | $169.00M | −$32.00M | -15.92% |
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Quarter ended Jun 2026 | $562.20M | +1.2% | +19.9% |
| Quarter ended Mar 2026 | $555.60M | +34.5% | +28.8% |
| Quarter ended Dec 2025 | $413.00M | -11.0% | +16.3% |
| Quarter ended Sep 2025 | $464.30M | -1.0% | +20.6% |
| Quarter ended Jun 2025 | $469.00M | +8.7% | +16.0% |
| Quarter ended Mar 2025 | $431.40M | +21.5% | +9.5% |
| Quarter ended Dec 2024 | $355.20M | -7.8% | -9.7% |
| Quarter ended Sep 2024 | $385.10M | -4.7% | +0.4% |
| Quarter ended Jun 2024 | $404.30M | +2.6% | -0.6% |
| Quarter ended Mar 2024 | $394.00M | +0.2% | -11.4% |
| Quarter ended Dec 2023 | $393.40M | +2.6% | -12.9% |
| Quarter ended Sep 2023 | $383.40M | -5.7% | -18.3% |
| Quarter ended Jun 2023 | $406.70M | -8.6% | -13.3% |
| Quarter ended Mar 2023 | $444.80M | -1.5% | -6.8% |
| Quarter ended Dec 2022 | $451.50M | -3.8% | +12.3% |
| Quarter ended Sep 2022 | $469.30M | +0.0% | +4.8% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
